Therapeutic effects of IL1 inhibitors

Many of the biological effects of IL-1 are similar to those observed after a severe infection (see Table 1). As a mediator produced in response to microbial invasion, IL-1 will induce fever, myalgia, somnolence, vasodilation and shock, cause bone resorption, induce muscle proteolysis, and induce synthesis of acute phase proteins such as C-reactive protein, serum amyloid A, and fibrinogen by hepatocytes. II.-1 causes a decrease in plasma zinc and iron, which in turn inhibits growth of virulent bacteria. IL-1 also induces chemokines that are responsible for neutrophil and macrophage emigration to sites of injury, all to arm the host against pathogens. Recent reports of the acquisition of soluble IL-1 type II receptors and inhibitors of ICE by certain viruses underscores the importance of IL-1 in host defense.

IL-1 has been implicated in vivo in the pathogenesis of a variety of acute and chronic inflammatory diseases such as septic shock, rheumatoid arthritis and atherosclerosis. Synovial fluids contain IL-1, which acts as a potent stimulator of cartilage resorption. Synovial tissue macrophages also produce high levels of IL-1 (3 followed by IL-lra. Endogenously produced IL-lra levels may be a normal response to limit the proinflammatory, pathogenic effects of IL-1.

A number of naturally occurring inhibitors of IL-1 are present in serum. PGE2 suppresses the synthesis and release of IL-1. CRH inhibits IL-l-induced anorexia, sleep and prostaglandin synthesis. Corticosteroids suppress expression of IL-1 mRNA. TGF(3, IL-4, IL-10 and IL-13 inhibit IL-1 production. (3-meI-anocyte-stimulating hormone inhibits the synthesis and activities of IL-1.

The role of the natural antagonist, IL-lra, in normal physiology remains to be understood. IL-lra can block IL-l-induced T cell proliferation, although 50% inhibition of IL-1 biological effects in vitro requires a 10- to 500-fold excess amount of IL-lra. IL-lra does not alter in vitro T cell proliferative responses to mitogens, antigens or alloantigens. IL-lra blocks LPS-induced IL-8 production in mononuclear cells. IL-lra also decreases IL-2 receptors and secretion of IL-la, IL-1 (3, IL-2 and TNF in these cells in vitro. Several studies have shown that inhibition of IL-lra by neutralizing antibodies results in considerable exacerbation of inflammatory diseases. Thus, IL-lra plays a role in downregulating in vivo inflammatory reactions. In animal models, IL-l-induced hypotension can be inhibited by pretreating the animals with large doses of IL-lra. However, the large amounts of IL-lra (10000-fold molar excess, 2.5 g day" ' estimated for human use) required to counteract IL-l-mediated effects reduces the clinical usefulness of IL-lra. Thus, IL-lra as yet has no significant therapeutic potential in human phase III clinical trials for sepsis. However, the demonstrated proinflammatory effect of suppressing IL-lra in vivo suggests that improved delivery systems may make IL-lra more effective.

Other approaches to block IL-l-mediated responses include the use of IL-l-specific antibodies, IL-1 receptor-specific antibodies, soluble IL-1 receptors and inhibitors of ICE.

Arthritis Relief Now

Arthritis Relief Now

When you hear the word arthritis, images of painful hands and joints comes into play. Few people fully understand arthritis and this guide is dedicated to anyone suffering with this chronic condition and wants relief now.

Get My Free Ebook


Post a comment